SYGNIS AG

euro adhoc: LION bioscience AG
Mergers - Acquisitions - Takeovers
Ad-hoc release: LION bioscience announces the take over of the operative business of Axaron Bioscience through acquisition of the shares in SYGNIS Bioscience GmbH & Co. KG by using the

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

05.07.2006

Heidelberg, July 5, 2006 - With the sale of its bioinformatics business unit  in March this year, LION bioscience AG disposed most of  its  operational  business and, thereby, reached a major milestone within the restructuring  process  which has been initiated at  the  end  of  2004.  As  a  consequence,  the  Management examined  various  alternatives  for  the  future  orientation    and evaluated different individual cases. Today, after approval of the supervisory board,  LION  bioscience  AG  signed  a contract together with two investment-companies of  the  family  of  SAP-founder Dietmar  Hopp,  BASF  Aktiengesellschaft  as  well  as  Axaron Bioscience    AG; according to this agreement LION bioscience AG shall acquire all shares  of  the company SYGNIS Bioscience GmbH & Co. KG which is owned by the other  contracting parties. Depending on the approval of its General Meeting, Axaron Bioscience  AG shall assign its entire operating business to SYGNIS Bioscience GmbH &  Co.  KG. Axaron Bioscience, which was founded in 1997, develops  with  its  35 employees promising novel therapies to treat neurodegenerative diseases. AX200, a  product for the treatment of strokes, is the most advanced compound and currently  being tested in a phase IIa clinical trial. Furthermore,  the  management  and  supervisory  board  of LION  bioscience  AG resolved on July 5, 2006 to use  78.6  percent of  its  authorized  capital  to acquire all the shares in SYGNIS Bioscience GmbH  &  Co.  KG.  In  exchange  for these  shares  some 7.8  million  new  LION  shares  will  be  issued  to    the shareholders of SYGNIS Bioscience GmbH & Co. KG. The new  shareholder structure after the transaction  will  be  as  follows:  Hopp  family 20.5  percent,  Dr. Friedrich von Bohlen and Halbach (founder and chairman of the supervisory  board of LION) 7.6 percent, BASF Aktiengesellschaft and Bayer  AG  5.1  percent  each, today's shareholders/freefloat of LION bioscience AG 61.7 percent.

@@start.t2@@Furthermore,  both  investment  companies  of    the    Hopp    family    and    BASF
Aktiengesellschaft committed further capital inflow  of  more  than  18  million
Euro in LION bioscience AG.
For further information, please contact:
|Peter Willinger                                      |Dr. Franz-Werner Haas                    |
|Chief Executive Officer                         |General Counsel                              |
|Tel: +49 (0) 6221-4038 293                    |Tel: +49 (0) 6221-4038 340            |
|Email:                                                    |Email:                                            |
|peter.willinger@lionbioscience.com        |franz.werner.haas@lionbioscience.c|
|                                                              |om                                                  |
|                                                              |                                                      |
###
Except for the historical information contained herein, the  matters  set  forth
in this press release are forward looking. These forward-looking statements  may
include  projections,  assumptions,  estimates,  targets,  and  descriptions  of
future events. Such statements are based on currently available information  and
on LION's current expectations as to future events that  may  not  prove  to  be
accurate. These statements are not guarantees of future performance and  involve
risks and uncertainties that are difficult to predict. Many factors could  cause
the actual results,  performance  or  achievements  of  LION  to  be  materially@@end@@

different from those that may be projected,  expected,  targeted, expressed  or implied by such statements. All roll-out plans and future dates with respect  to completion of development and market release of LION products are  target  dates only based on the company's current planning and may change in the  future.  Any delays in the current product release schedule will have  a  materially adverse effect on the company's targets for fiscal year. ###

@@start.t3@@end of announcement                                                 euro adhoc 05.07.2006 21:25:35
--------------------------------------------------------------------------------@@end@@

ots Originaltext: LION Bioscience AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476
E-Mail: stephan.trautvetter@lionbioscience.com

Branche: Biotechnology
ISIN:      DE0005043509
WKN:        504350
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurter Wertpapierbörse / regulated dealing/prime
              standard
              New York / ADR
              Börse Berlin-Bremen / free trade
              Hamburger Wertpapierbörse / free trade
              Baden-Württembergische Wertpapierbörse / free trade
              Börse Düsseldorf / free trade
              Niedersächsische Börse zu Hannover / free trade
              Bayerische Börse / free trade



Das könnte Sie auch interessieren: